loading...| Preferred Name |
Evolocumab |
|
| Synonyms |
AMG 145 AMG-145 AMG145 EVOLOCUMAB Evolocumab Repatha |
|
| Definitions |
A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, evolocumab targets, binds to and inhibits the activity of PCSK9. This prevents binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C174672 |
|
| CAS_Registry |
1256937-27-5 |
|
| code |
C174672 |
|
| Concept_In_Subset | ||
| Contributing_Source |
FDA |
|
| DEFINITION |
A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, evolocumab targets, binds to and inhibits the activity of PCSK9. This prevents binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver. |
|
| FDA_UNII_Code |
LKC0U3A8NJ |
|
| FULL_SYN |
AMG 145 AMG-145 AMG145 EVOLOCUMAB Evolocumab Repatha |
|
| label |
Evolocumab |
|
| NCI_Drug_Dictionary_ID |
808340 |
|
| NCI_META_CUI |
CL1412172 |
|
| Preferred_Name |
Evolocumab |
|
| prefixIRI |
Thesaurus:C174672 |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance |
|
| subClassOf |